Remove 2027 Remove Regulations Remove Vaccine
article thumbnail

Fourth IHR Emergency Meeting on 2024 Mpox Surge – Temporary Recommendations

The Pharma Data

WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health Regulations (2005) Emergency Committee on 5 June 2025.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

What we expect European regulators to do in August and September 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people

The Pharma Data

Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2027, except upon the occurrence of an early release event provided for under Article R. The voting rights attached to the subscribed Shares will be exercised directly by the employees.

article thumbnail

Analysis Life Sciences Thank You BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions

Agency IQ

” Interchangeable products can be substituted for the reference product at the pharmacy level, without prescriber intervention, within state and local regulations. By contrast, a biosimilar product is only “highly similar to and has no clinically meaningful differences in terms of safety, purity, and potency.”

article thumbnail

c-LEcta Continues Its Growth in 2020 and Increases Its EBITDA Above Average

The Pharma Data

A product called DENARASE, which is used in gene and cell therapy, but is also required for production of certain types of vaccines, was the biggest driver of growth in 2020. Therefore, significant momentum came from vaccine development and production in 2020. The kit can be used to detect DENARASE residues. About c-LEcta.

article thumbnail

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

BioPharma Drive: Drug Pricing

It has about $1 billion in debt due in 2027 and intends to speak with lenders this week to determine whether any of the myriad recent developments might constitute a “material adverse event” that could trigger financial fallout, executives told Leerink’s Schwartz. But Sarepta could face more financial peril still.

article thumbnail

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

RE47,739 (‘739) by more than four years until March 5, 2027. IBRANCE is an oral inhibitor of CDKs 4 and 6, 1 which are key regulators of the cell cycle that trigger cellular progression. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate extends the term of U.S. 2,3 In the U.S.,